Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).
Fiche publication
Date publication
août 2012
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel, Dr KAMINSKY Marie-Christine, Dr ZANETTA Sylvie
Tous les auteurs :
Schmitz S, Kaminsky-Forrett MC, Henry S, Zanetta S, Geoffrois L, Bompas E, Moxhon A, Mignion L, Guigay J, Knoops L, Hamoir M, Machiels JP
Lien Pubmed
Résumé
Preclinical studies suggest that insulin-like growth factor-1 receptor (IGF-1R) blockage could be a promising therapeutic target in squamous cell carcinoma of the head and neck (SCCHN). Therefore, we investigated the efficacy and toxicity of figitumumab, an anti-IGF-1R monoclonal antibody, in palliative SCCHN.
Mots clés
Antibodies, Monoclonal, Biopsy, Carcinoma, Squamous Cell, blood, Gene Expression Profiling, Head and Neck Neoplasms, blood, Humans, Immunoglobulins, Intravenous, adverse effects, Receptor, IGF Type 1, antagonists & inhibitors, Reverse Transcriptase Polymerase Chain Reaction
Référence
Ann. Oncol.. 2012 Aug;23(8):2153-61